AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38811992 — intervention group
Group type: EXPERIMENTAL
Intervention: D + T + EP
Number of subjects: 805
Study 38811992 — intervention group
Group type: COMPARATOR
Intervention: D + EP
Number of subjects: 805
Study 38811992 — intervention group
Group type: COMPARATOR
Intervention: EP
Number of subjects: 805
Study 38811998 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor based treatment (empagliflozin and linagliptin)
Number of subjects: 65
Study 38811998 — intervention group
Group type: COMPARATOR
Intervention: Non-SGLT2 inhibitor based treatment (metformin and insulin)
Number of subjects: 65
Study 38812037 — intervention group
Group type: EXPERIMENTAL
Intervention: SPARC
Number of subjects: 31
Study 38812037 — intervention group
Group type: EXPERIMENTAL
Intervention: LDLJ
Number of subjects: 31
Study 38812037 — intervention group
Group type: EXPERIMENTAL
Intervention: TDSM
Number of subjects: 31
Study 38812047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 93
Study 38812047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle + medical food
Number of subjects: 93
Study 38812047 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 93
Study 38812073 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Health Worker (CHW) supported teleaudiology hearing aid services
Number of subjects: 28
Study 38812073 — intervention group
Group type: COMPARATOR
Intervention: Non-Community Health Worker (non-CHW) group
Number of subjects: 28
Study 38812378 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand Task (HT) group - 45 minutes of task-oriented training with robotic hand for 20 sessions
Number of subjects: 34
Study 38812378 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) group - 45 minutes of hand-functional exercises without objects using the same robot
Number of subjects: 34
Study 38812507 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated with two doses of CoronaVac, 2 to 8 weeks post-infection
Number of subjects: 12
Study 38812507 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection in the pediatric population vaccinated with an inactivated SARS-CoV-2 vaccine
Number of subjects: 12
Study 38812955 — intervention group
Group type: EXPERIMENTAL
Intervention: Full app containing all intervention modules
Number of subjects: 761
Study 38812955 — intervention group
Group type: COMPARATOR
Intervention: Educational only app containing only the educational content
Number of subjects: 761
Study 38813112 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexagratinib 80 mg bd on a continuous schedule until disease progression or unacceptable toxicity
Number of subjects: 12
Study 38813261 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) in persons with HIV (PWH)
Number of subjects: 39
Study 38813388 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP1815 (1 capsule daily)
Number of subjects: 0
Study 38813388 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP1815 (4 capsules daily)
Number of subjects: 0
Study 38813388 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP1815 (10 capsules daily)
Number of subjects: 0
Study 38813388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38813446 — intervention group
Group type: EXPERIMENTAL
Intervention: Vosoritide (15 μg/kg/day, daily subcutaneous injection)
Number of subjects: 26
Study 38813444 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (blueberry juice and extract, tryptophan 2 g, tyrosine 10 g)
Number of subjects: 103
Study 38813444 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical appearing inert substance)
Number of subjects: 103
Study 38813551 — intervention group
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M™ vaccine at varied doses (10µgR21/50 µg Matrix-M™, 5µgR21/25µg Matrix-M™, 5µgR21/50µg Matrix-M™)
Number of subjects: 91
Study 38813551 — intervention group
Group type: EXPERIMENTAL
Intervention: R21/Matrix-M™ vaccine
Number of subjects: 91
Study 38813815 — intervention group
Group type: EXPERIMENTAL
Intervention: ML GSP model based on clinical and CT image features
Number of subjects: 301
Study 38813815 — intervention group
Group type: COMPARATOR
Intervention: Radiomics model
Number of subjects: 301
Study 38813838 — intervention group
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA (onabotA) treatment
Number of subjects: 744
Study 38813933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealer-based obturation technique (SBO) with calcium silicate sealer (CSS)
Number of subjects: 194
Study 38813933 — intervention group
Group type: COMPARATOR
Intervention: Warm-vertical compaction (WVC) with resin-based sealer (RBS)
Number of subjects: 194
Study 38813962 — intervention group
Group type: COMPARATOR
Intervention: Above-elbow cast
Number of subjects: 97
Study 38813962 — intervention group
Group type: EXPERIMENTAL
Intervention: Above/below-elbow cast
Number of subjects: 97
Study 38813962 — intervention group
Group type: COMPARATOR
Intervention: Malunion group
Number of subjects: 97
Study 38813962 — intervention group
Group type: EXPERIMENTAL
Intervention: No malunion group
Number of subjects: 97
Study 38814000 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute bronchodilation treatment, specific details not available.
Number of subjects: 0
Study 38814132 — intervention group
Group type: COMPARATOR
Intervention: Daridorexant 50 mg
Number of subjects: 0
Study 38814132 — intervention group
Group type: COMPARATOR
Intervention: Daridorexant 25 mg
Number of subjects: 0
Study 38814132 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 38814264 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-hydroxymethylcytosine (5hmC) biomarkers in circulating cell-free DNA (cfDNA)
Number of subjects: 2576
Study 38814343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment serum histidine concentration
Number of subjects: 0
Study 38814343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment serum glutamate concentration
Number of subjects: 0
Study 38814343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment serum phenylalanine concentration
Number of subjects: 0
Study 38814343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment serum tyrosine concentration
Number of subjects: 0
Study 38814343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment serum valine concentration
Number of subjects: 0
Study 38814433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 4 weeks (Q4W)
Number of subjects: 0
Study 38814433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE) 80 mg every 2 weeks (Q2W)
Number of subjects: 0
Study 38814433 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXE)
Number of subjects: 0
Study 38814433 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 0
Study 38814525 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed Field Ablation (PFA) with FARAPULSE™ system
Number of subjects: 752
Study 38814525 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 752
Study 38814532 — intervention group
Group type: EXPERIMENTAL
Intervention: Troriluzole
Number of subjects: 218
Study 38814532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study 38814627 — intervention group
Group type: EXPERIMENTAL
Intervention: Lay health worker-led advance care planning intervention
Number of subjects: 213
Study 38814627 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 213
Study 38814681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health chatbot app (Wysa) used over a period of 4 weeks
Number of subjects: 68
Study 38814681 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 68
Study 38814681 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental health chatbot app (Wysa)
Number of subjects: 68
Study 38814692 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT invitations via automated confidential SMS text messages
Number of subjects: 600
Study 38814692 — intervention group
Group type: COMPARATOR
Intervention: Physical invitation cards alone
Number of subjects: 600
Study 38814692 — intervention group
Group type: EXPERIMENTAL
Intervention: CONSORT intervention
Number of subjects: 600
Study 38814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT)
Number of subjects: 0
Study 38814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologics
Number of subjects: 0
Study 38814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of OIT and biologics
Number of subjects: 0
Study 38814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 38814736 — intervention group
Group type: EXPERIMENTAL
Intervention: Other biologics
Number of subjects: 0
Study 38814736 — intervention group
Group type: EXPERIMENTAL
Intervention: New therapeutic strategies
Number of subjects: 0
Study 38814827 — intervention group
Group type: EXPERIMENTAL
Intervention: ANNE sensors (multimodal, wireless wearable sensor system)
Number of subjects: 76
Study 38814827 — intervention group
Group type: COMPARATOR
Intervention: ApneaLink Air (standard home sleep apnea test)
Number of subjects: 76
Study 38815111 — intervention group
Group type: EXPERIMENTAL
Intervention: Unflavored, sucralose-sweetened electronic cigarette
Number of subjects: 0
Study 38815111 — intervention group
Group type: COMPARATOR
Intervention: Combustible cigarettes
Number of subjects: 0
Study 38815151 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib, starting dose of 135 mg/m2/dose, administered twice daily for 28-day cycles.
Number of subjects: 18
Study 38815152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 730
Study 38815152 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 730
Study 38815164 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical surveillance of microbiology data
Number of subjects: 82
Study 38815164 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical surveillance of microbiology data (pre-pandemic)
Number of subjects: 82
Study 38815164 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical surveillance of microbiology data (pandemic)
Number of subjects: 82
Study 38815164 — intervention group
Group type: COMPARATOR
Intervention: Control group (without alerting infection prevention programs)
Number of subjects: 82
Study 38815164 — intervention group
Group type: COMPARATOR
Intervention: Control group (pre-pandemic)
Number of subjects: 82
Study 38815164 — intervention group
Group type: COMPARATOR
Intervention: Control group (pandemic)
Number of subjects: 82
Study 38815173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU) four times daily for 8 weeks
Number of subjects: 61
Study 38815173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 38815173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 61
Study 38815178 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonal hematopoiesis-associated mutations (CHm) identified through liquid biopsy
Number of subjects: 255
Study 38815188 — intervention group
Group type: EXPERIMENTAL
Intervention: REDCap Clinical Data Interoperability Services (CDIS) module
Number of subjects: 73
Study 38815188 — intervention group
Group type: COMPARATOR
Intervention: EHR relational databases (UChicago's Clinical Research Data Warehouse and VUMC's Epic Clarity database)
Number of subjects: 73
Study 38815230 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized Pain Plans (IPPs) implemented in the emergency department
Number of subjects: 153
Study 38815230 — intervention group
Group type: COMPARATOR
Intervention: Baseline comfort managing VOEs
Number of subjects: 153
Study 38815230 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-IPP implementation comfort managing VOEs
Number of subjects: 153
Study 38815230 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordering of recommended medication by providers
Number of subjects: 153
Study 38815230 — intervention group
Group type: EXPERIMENTAL
Intervention: Intention to use IPPs by providers
Number of subjects: 153
Study 38815694 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with 50-60 Gy in 5-8 fractions, using online magnetic resonance (MR) image-guidance on a 1.5 T MRI-linac.
Number of subjects: 28
Study 38815694 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 28
Study 38815760 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation Treatment for Anhedonia
Number of subjects: 116
Study 38815760 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Number of subjects: 116
Study 38815760 — intervention group
Group type: COMPARATOR
Intervention: Both forms of psychotherapy
Number of subjects: 116
Study 38815756 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 plasma
Number of subjects: 0
Study 38815756 — intervention group
Group type: COMPARATOR
Intervention: RNA aptamer that neutralizes histones
Number of subjects: 0
Study 38815756 — intervention group
Group type: EXPERIMENTAL
Intervention: EVs isolated from COVID-19 plasma
Number of subjects: 0
Study 38815953 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired-VNS
Number of subjects: 108
Study 38815953 — intervention group
Group type: COMPARATOR
Intervention: Control (sham-VNS)
Number of subjects: 108
Study 38816042 — intervention group
Group type: EXPERIMENTAL
Intervention: Care bundle implementation
Number of subjects: 0
Study 38816042 — intervention group
Group type: COMPARATOR
Intervention: Pre-implementation period
Number of subjects: 0
Study 38816040 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised, patient-centred rehabilitation
Number of subjects: 36
Study 38816040 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsychosocial approach to rehabilitation
Number of subjects: 36
Study 38816040 — intervention group
Group type: EXPERIMENTAL
Intervention: Uniform communication between caregivers
Number of subjects: 36
Study 38816040 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined roles of interprofessional team members
Number of subjects: 36
Study 38816040 — intervention group
Group type: EXPERIMENTAL
Intervention: Accessible case manager
Number of subjects: 36
Study 38816040 — intervention group
Group type: EXPERIMENTAL
Intervention: Return to work
Number of subjects: 36
Study 38816044 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical characteristics and diagnostic predictors for CAP
Number of subjects: 954
Study 38816055 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol infusions
Number of subjects: 15
Study 38816058 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Wisely (PW)
Number of subjects: 60
Study 38816232 — intervention group
Group type: EXPERIMENTAL
Intervention: NeoExpand (neoantigen-specific stimulation of TILs)
Number of subjects: 25
Study 38816400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific enteral nutrition formula (low glycaemic index carbohydrates, fibre (80% soluble), higher lipid content)
Number of subjects: 52
Study 38816400 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric isoprotein formula (control group)
Number of subjects: 52
Study 38816400 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific enteral nutrition formula (EG)
Number of subjects: 52
Study 38816400 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 38816482 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 120
Study 38816482 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 300 mg per day
Number of subjects: 120
Study 38816482 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of EA and CBZ
Number of subjects: 120
Study 38816482 — intervention group
Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 120
Study 38816482 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 38816482 — intervention group
Group type: COMPARATOR
Intervention: Sham EA plus placebo
Number of subjects: 120
Study 38816482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to EA
Number of subjects: 120
Study 38816482 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to CBZ
Number of subjects: 120
Study 38816554 — intervention group
Group type: EXPERIMENTAL
Intervention: SFD (sinus filling defect)
Number of subjects: 188
Study 38816554 — intervention group
Group type: EXPERIMENTAL
Intervention: HALT (hypoattenuated leaflet thickening)
Number of subjects: 188
Study 38816554 — intervention group
Group type: EXPERIMENTAL
Intervention: SFD
Number of subjects: 188
Study 38816592 — intervention group
Group type: EXPERIMENTAL
Intervention: PrEP iT! mHealth intervention
Number of subjects: 80
Study 38816592 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 80
Study 38816609 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal assessment combining behavioral, neuroimaging, and electrophysiological markers
Number of subjects: 349
Study 38816609 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal assessment
Number of subjects: 349
Study 38816787 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic multimorbidity patterns identified through fuzzy c-means cluster analysis.
Number of subjects: 3988
Study 38816787 — intervention group
Group type: EXPERIMENTAL
Intervention: Trajectories of chronic conditions over time.
Number of subjects: 3988
Study 38816787 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratification by sex and age group.
Number of subjects: 3988
Study 38816810 — intervention group
Group type: EXPERIMENTAL
Intervention: EAdi-based parameters during SBT
Number of subjects: 35
Study 38816810 — intervention group
Group type: EXPERIMENTAL
Intervention: EAdi changes during SBT
Number of subjects: 35
Study 38816810 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in EAdi and neuro-discharge per min
Number of subjects: 35
Study 38816821 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological age determination by DNA methylation profile
Number of subjects: 321
Study 38816821 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual frailty assessment
Number of subjects: 321
Study 38816821 — intervention group
Group type: EXPERIMENTAL
Intervention: Tyrosine kinase inhibitors
Number of subjects: 321
Study 38816821 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 321
Study 38816826 — intervention group
Group type: EXPERIMENTAL
Intervention: Exertional desaturation during exercise testing
Number of subjects: 148
Study 38816826 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise testing with continuous pulse oximetry
Number of subjects: 148
Study 38816826 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized, risk-adapted therapy
Number of subjects: 148
Study 38816854 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic motor competence (BMC) training
Number of subjects: 0
Study 38816854 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical fitness (PF) training
Number of subjects: 0
Study 38816854 — intervention group
Group type: EXPERIMENTAL
Intervention: Executive function (EF) training
Number of subjects: 0
Study 38817362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 43
Study 38817362 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 38818022 — intervention group
Group type: EXPERIMENTAL
Intervention: Confident, Active and Happy Youth (CAHY) intervention, 14-session manualized physical activity-based intervention
Number of subjects: 0
Study 38818519 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) for 6 months
Number of subjects: 128
Study 38818519 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 128
Study 38818766 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of underlying cardiac abnormalities
Number of subjects: 213
Study 38818766 — intervention group
Group type: EXPERIMENTAL
Intervention: TR severity grades (none-trace, mild, moderate-severe)
Number of subjects: 213
Study 38818766 — intervention group
Group type: EXPERIMENTAL
Intervention: TV remodelling parameters (annular dilatation, tenting area)
Number of subjects: 213
Study 38818766 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive remodelling of right-heart chambers and TV geometry
Number of subjects: 213
Study 38818769 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented circuit training (TOCT) combined with myofascial release
Number of subjects: 26
Study 38818769 — intervention group
Group type: COMPARATOR
Intervention: Control group (TOCT only)
Number of subjects: 26
Study 38818887 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg once daily for 52 weeks
Number of subjects: 150
Study 38818888 — intervention group
Group type: EXPERIMENTAL
Intervention: Fezolinetant 30 mg/day
Number of subjects: 301
Study 38818888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 301
Study 38818934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongericimab 150 mg every 2 weeks
Number of subjects: 806
Study 38818934 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongericimab 300 mg every 4 weeks
Number of subjects: 806
Study 38818934 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo every 2 weeks
Number of subjects: 806
Study 38818934 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo every 4 weeks
Number of subjects: 806
Study 38818936 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent exacerbators
Number of subjects: 1000
Study 38818936 — intervention group
Group type: COMPARATOR
Intervention: Infrequent exacerbators
Number of subjects: 1000
Study 38819031 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorlatinib
Number of subjects: 296
Study 38819031 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib
Number of subjects: 296
Study 38819408 — intervention group
Group type: EXPERIMENTAL
Intervention: IP nivolumab (0.5, 1, or 3 mg/kg)
Number of subjects: 17
Study 38819500 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 1052
Study 38819500 — intervention group
Group type: COMPARATOR
Intervention: Formula feeding
Number of subjects: 1052
Study 38819500 — intervention group
Group type: EXPERIMENTAL
Intervention: Green stool color
Number of subjects: 1052
Study 38819500 — intervention group
Group type: EXPERIMENTAL
Intervention: Occasional blood in stool
Number of subjects: 1052